博實股份(002698.SZ):聯創未來完成減持3%股份
格隆匯7月3日丨博實股份(002698.SZ)公佈,2025年7月3日,公司收到聯創未來出具的《關於股份減持計劃完成暨減持結果的告知函》,聯創未來在2025年6月17日至2025年7月3日期間通過大宗交易及集中競價交易的方式減持公司股份8,130,715股,佔公司總股本的0.7951%,本次權益變動後,聯創未來持有公司股份114,499,861股,持股比例由11.9925%減少至11.1974%。截至2025年7月3日,聯創未來本次減持計劃已實施完成,本次減持計劃累計減持公司股份30,676,815股,佔公司總股本的3.0000%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.